Pre-made Ansuvimab benchmark antibody ( Whole mAb, anti-Zaire Ebolavirus GP1 therapeutic antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-ab-028

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-ab-028 Category Tag

Product Details

Pre-Made Ansuvimab biosimilar, Whole Mab: Anti-Zaire Ebolavirus GP1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Ansuvimab, sold under the brand name Ebanga, is a monoclonal antibody medication for the treatment of Zaire ebolavirus (Ebolavirus) infection.

Products Name (INN Index)

Pre-Made Ansuvimab biosimilar, Whole Mab: Anti-Zaire Ebolavirus GP1 therapeutic antibody

INN Name

Ansuvimab

Target

Zaire Ebolavirus GP1

Format

Whole mAb

Derivation

NA

Species Reactivity

Human

CH1 Isotype

IgG1

VD LC

Kappa

Highest_Clin_Trial (Jan '20)

Approved

Est. Status

Active

100% SI Structure

None

99% SI Structure

5fha:HL/5fhc:HL

95-98% SI Structure

None

Year Proposed

2020

Companies

Ridgeback Biotherapeutics

Conditions Approved

Zaire ebolavirus infection

Conditions Active

NA

Conditions Discontinued

NA

Development Tech

NA

Previous Name

NA

Gm Offical Target Name

Zaire Ebolavirus GP1

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide